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Counseling patients with DCIS in a rational manner can be extremely diﬃcult when the range of treatment criteria results in
diverse and confusing clinical recommendations. Surgeons need tools that quantify measurable prognostic factors to be used
in conjunction with clinical experience for the complex decision-making process. Combination of statistically signiﬁcant tumor
recurrence predictors and lesion parameters obtained after initial excision suggests that patients with DCIS can be stratiﬁed into
speciﬁc subsets allowing a scientiﬁcally based discussion. The goal is to choose the treatment regimen that will signiﬁcantly beneﬁt
eachpatientgroupwithoutsubjectingthepatientstounnecessaryrisks.Exploringtheeﬀectivenessofcompleteexcisionmayoﬀera
starting place in a new way of reasoning and conceiving surgical modalities in terms of “downscoring” or “upscoring” patient risk,
perhapschangingclinicalapproach.Reexcisonmaylowerthespeciﬁcsubsets’scoreandimprovelocalrecurrence-freesurvivalalso
by revealing a larger tumor size, a higher nuclear grade, or an involved margin and so suggesting the best management. It seems,
thatthekeycouldbeidentifyingsigniﬁcantrelapsepredictivefactors,accordingtovalidatedriskinvestigationmodels,whosevalue
is modiﬁable by the surgical approach which avails of diﬀerent diagnostic and therapeutic potentials to be optimal. Certainly DCIS
clinical question cannot have a single curative mode due to heterogeneity of pathological lesions and histologic classiﬁcation.
1.Introduction
1.1. Biopathological Proﬁle. Ductal carcinoma in situ (DCIS)
representsaheterogeneousgroupofproliferationsvaryingin
cytological and architectural appearance, for some of which
it is believed that there are major clinical consequences [1].
Some studies have documented the sharing of molecular and
genotypic characteristics in diﬀerent benign and malignant
stages of progression. Comparative analyses for implement-
ing predictive markers in tumour biology show a multitude
of genetic alterations in all the DCIS cases and propose
distinct pathways in morphological evolution (poor, inter-
mediate, and well). Poorly diﬀerentiated diseases displayed
a higher frequency of ampliﬁcations (17q12, 11q13) and a
higher average rate of genetic imbalances (40%) suggesting a
developmental progression model for intraductal carcinoma
[2]. Although the biological impact of these ﬁndings is not
yetknown,itislikelythatDCISdiﬀersbygeneticgradingand
thus in prognostic implications. In fact the main question
relating to the treatment is whether to consider DCIS a
direct precursor of invasive cancer [3]. The natural history
of small, noncomedo, and low grade in situ lesions treated
by biopsy alone has been evaluated in studies with long-term
follow-up. In the series reported by Sanders et al. 11 of 28
women (39.3%) have developed invasive breast carcinoma
(IBC) after a median of thirty-one years, and 5 of 11 women
(45%) died of metastatic disease [4]. In similar ﬁndings the
risk of invasive disease has been described in a range of 14–
75% of cases conﬁrming a total progression impact of 43%.
This has led to a rapidly consensus that atypical intraductal
hyperplasia (AIDH) indicates a small, generalized, increased
risk of breast carcinoma in both breasts that is approximately
one half of low-grade DCIS lesions [5]. In our opinion, a
practicaldiﬀerencebetweenthesediagnosesleadstoadeeper
level of understanding the rational therapeutics but it is also
one of the most critical intersections of histopathology and2 International Journal of Surgical Oncology
clinical management today. With the diagnostic increase,
the aim is to accurately identify clinically relevant lesions
and streamline the treatment strategies. This emphasizes the
signiﬁcance of conceiving a less aggressive therapy (local
excision only) when these lesions are limited in size, and
the recurrence interval may well be beyond a reasonable life
expectancy for the patient.
2. EvolvingKnowledge
2.1. Critical Insights into Epidemiology. Percentage of carci-
noma in situ (including DCIS and LCIS) from cancers diag-
nosed in the arm of selected screening studies now accounts
for about 20–25% of all cases and from 17 to 34% of mam-
mography detection [6].
In the United States, DCIS incidence rose from 1.87 per
100000 in 1973–1975 to 32.5 in 2004 [3]. Data from the
Surveillance and End Results program depict about a 500%
increase in DCIS among women aged 50 years and older
from 1983 to 2003 with incidence starting to decline in 2003.
An opposite trend has been veriﬁed among younger women
in whom there has been a 290% increase since 1983 and the
incidence continues to rise [7]. In addition, the prevalence
of comedo subtype has not increased as rapidly as the less
aggressive forms across all age groups. An analysis based
on cancer registries found that between 1991 and 2001 the
age-adjusted incidence of comedo DCIS was unchanged at
approximately seven per 100000 rose from 16.5 to 31 per
100000 for noncomedo lesions [8] .T h ea c t u a lp r e v a l e n c ei n
the population is diﬃcult to estimate because most patients
are asymptomatic [7], but an improved understanding of
information regarding frequency and risk factors could lead
to critical insights into biological implications.
2.2. Classiﬁcation Debate. Diﬀerent classiﬁcation systems
may have important implications in clinical and prognos-
tic management. No single scheme has been universally
accepted and experts disagree as to which is the most appro-
priate [9].
The problem areas consist of the diﬃculties in separat-
ing low-grade DCIS from atypical intraductal hyperplasia
(AIDH) and accurately deﬁning disease size and extent.
Moreover,duetothesubjectiveinterpretationofarchitecture
and predictive features such as nuclear grade, necrosis, and
polarization, many experienced pathologist diﬀer in their
diagnosis of DCIS [10].
According to the European Pathologist Working Group
(EPWG) classiﬁcation (G1, G2, G3), adopted by the Euro-
pean Organization for the Research and Treatment of
Cancer (EORT), all the lesions are divided into three classes
reﬂecting a statistically diﬀerent association between nuclear
grade and recurrence (P.009) [11].
TheVanNuysPrognosticindex(VNPI)wasdevelopedto
aid in the complex treatment selection process also including
age, tumor size, and margin width to place patients in cate-
gories corresponding to clinical algorithms (Table 1). Patho-
logical classiﬁcation combines high nuclear grade and co-
medo-type necrosis to predict clinical behavior and stratify
disease into three groups: non-high-nuclear grade without
comedo-type necrosis (Score 1), or with necrosis (Score 2)
and high nuclear grade (Score 3).
Silverstein et al. recently reported 31 local recurrences in
238 patients after breast-conservation surgery, 3.8% (3/80)
in group 1, 11.1% (10/90) in group 2, and 26.5% (18/68)
in group 3. The 8-year actuarial disease-free survivals were
93%,84%,and61%,respectively(allP ≤ 0.05)[1].However,
according to our experience, tissue processing by the Van
Nuys protocol is complex, thus limiting its feasibility in clin-
ical practice.
Traditionally, highly heterogeneous intraductal prolifer-
ative lesions have been subdivided into noncancer—intra-
ductal hyperplasia (IDH) and atypical intraductal hyper-
plasia (AIDH)—and cancer—DCIS, grades 1, 2, and 3.
According to Tavassoli FA viewpoint a recognized problem
with current classiﬁcation is the interobserver variability and
lack of reproducibility in lesions assignment with similar
morphologic, immunohistochemical, and molecular charac-
teristics. There is, for example, no justiﬁcation in separating
AIDH from low-grade DCIS because of their simply diﬀer-
ences in size and quantity [10].
Moreover, the possibility of misunderstanding ﬂorid
ductal hyperplasia is also really concrete. A review of 350
DCIS by expert breast pathologists resulted in a change in
treatment recommendations in 93 (43%) cases and a con-
clusion that an expert assessment is necessary in this context
[12].
According to Tavassoli the designation of carcinoma in
situ is to be abandoned and it is necessary to unify the intra-
ductal proliferations or alterations under the designation of
ductal intraepithelial neoplasia (DIN) lesions that constitute
risk factors for subsequent development of invasive carci-
noma. TherearethreeDINcategories,DIN-1toDIN3. DIN-
1 includes IDH (grade 1a), AIDH (grade 1b), and grade
1 DCIS (grade 1c); DIN-2 includes grade 2 DCIS; DIN-3
includes grade 3 DCIS [13].
InfactO’Connelletal.inthemostcomprehensiveassess-
ment of loss of heterozygosity (LOH) among intraductal
proliferations showed that LOH of at least one genetic locus
was shared with the synchronous invasive cancer in 37% of
19 patients with usual ductal hyperplasia (IDH), 45% of 11
patients with AIDH, 77% of 13 patients with non-comedo
DCIS, and 80% of 11 patients with comedo DCIS [14].
In conclusion, DIN system oﬀered a translational table
for conversion of the currently used terminology of DCIS.
This could lead to decrease impact of having two drastically
diﬀerent designations of cancer (DCIS) and noncancer
(AIDH) applied to same lesions, caused by interobserver
variability, reducing also geographically the term cancer-
related overtreatment possibilities.
However, there are limitations to this classiﬁcation, such
as the inclusion of IDH among neoplasias, that may cause
undue concern for those not aware that a tumor can be
totally benign.
We think that analyzing with emphasis the areas of con-
troversy and exciting new research prospects could enhance
consistency in the interpretation and reporting of such com-
plex and challenging disease.International Journal of Surgical Oncology 3
Table 1: The USC/VNPI scoring system.
Van Nuys Prognostic Index
Parameter Score 1 Score 2 Score 3
Van Nuys Classiﬁcation Group 1 Group 2 Group 3
Non high nuclear grade without
necrosis
Nonhigh nuclear grade with
necrosis
High nuclear gradewith or
without necrosis
Margins ≥10mm 1–9mm <1mm
Size <15mm 16–40mm >40mm
Age >60 40–60 <40
Modiﬁed from Silverstein; Ductal Carcinoma in situ of the breast 2nd ed. 2002.
Table 2
Author and reference Parameter Results
Ottesen et al. [15] Size 10-year LR rates of DCIS treated by BCS alone (n = 275)
<10mm LR 11%
>10mm LR 48%
Cutuli et al. [29] Size 5-year LR rates of BCS versus BCS + RT groups (n = 1,289)
<10mm LR 30% LR 11%
>10mm LR 31% LR 13%
Dunne et al. [18]M a r g i n Optimum margin threshold for DCIS resection (n = 2,514)
Number of patients Negative Margin Width Percentage of patients with IBTR (5-year follow-up)
914 No cells on ink 9.4
1,239 1mm margin 10.4
207 2mm margin 5.8
154 ≥5mmmargin 3.9
Kerlikowske et al. [57] Nuclear Grade Invasive LR rates of DCIS treated by BCS alone (N = 1491)
MacDonald et al. [43]
Low-grade lesions 6%
High-grade lesions 31.5%
Silverstein et al. [1]V N P I S c o r e LR rates and DFS in three groups of DCIS patients (N = 238)
(1) Non-high-grade DCIS without comedo-type necrosis 3.8% 93%
(2) Non-high-grade DCIS with comedo-type necrosis 11.1% 84%
(3) High-grade DCIS with or without comedo-type necrosis 26.5% 61%
2.3. Pathological and Predictive Features. In view of the
increasing number of patients treated with breast conserving
treatment (BTC) for ductal carcinoma in situ, risk factors for
recurrence and metastasis should be identiﬁed (Table 2).
The size of DCIS lesions has been correlated with LR but
several studies have been criticized for performance in this
regard.
Results by Ottesen et al. after 10-year follow-up reported
a local recurrence (LR) rate of 11% and 48% for lesions
smaller and larger than 10mm, respectively, showing a sig-
niﬁcant association with a speciﬁc threshold [15]. However
theseﬁndingswerenotsupportedbytheFrenchCancerCen-
tre’s experience which identiﬁed LR rates of 30% and 31% in
B C Sg r o u pf o rl e s i o n su n d e ro ro v e r1 0m mr e s p e c t i v e l y ,a n d
11%and13%forthesamesubgroupsintheBCS+RTgroup
[16].
Surgical clearance is considered the most important risk
factor for local recurrence and consensus has yet to be
reached about optimal margin width. On univariate analysis
Neuschatz et al. found that margin width and lesions size of
initial excision specimens are signiﬁcantly predicted for the
presence of residual DCIS on reexcision. Residual tumor was
found on reexcision in 41% of greater than 0-1mm, 31% of
greater than 1-2mm, and 0% of greater than 2mm clearance
(P<0001) [17].
In fact inadequate margins may result in high local
recurrence, and excessively large resections may lead to poor
cosmetic outcome without oncologic beneﬁt.4 International Journal of Surgical Oncology
In a recent meta-analysis when a 5mm or greater margin
was compared with a margin of 2mm, no signiﬁcance dif-
ference in the risk of IBTR (3.8% versus 5.8%) was observed
(OR = 1.51; 95% CI, 0.51 to 5.04; P>. 0 5 ) .H o w e v e r ,w h e n
speciﬁc margin threshold was examined, a 2mm margin was
found to be superior to a margin less than 2mm (10.4%; OR
0.53; 95%CI, 0.26 to 0.96; P<. 05) [18].
Women with high nuclear grade DCIS or clinical exhibi-
tion treated by lumpectomy may be appropriate candidates
for additional treatment.
Studies of DCIS treated by BCS alone have reported LR
rates ranging from 6% for low grade up to 31.5% for high-
grade lesions [19].
Ottesen et al. supported the consideration of large cell/
high grade DCIS as a biologically aggressive lesion with high
recurrence rate and conﬁrmed a low malignant potential
with low failure rate at short-term follow-up and a delayed
pattern of development for small and low type [15].
Histopathologically, in DCIS a strong association was
found between large nuclear size and comedonecrosis as
independent signiﬁcant predictors. The recurrence rate
among the high-grade/comedo-type lesions was 40%, 47%,
19%, and 33%, respectively, in diﬀerent series treated by
BCS alone [20–23]. The signiﬁcance of comedo-type as a
risk factor for LR has resulted in its inclusion in prognostic
indices. The Van Nuys classiﬁcation combines both features
to deﬁne three distinct groups with predictive utility after
BCS and facilitating clinical decision making [24].
3. Management
3.1. Clinical Practice. Based on the results of the several
studies it is clear that DCIS represents a broad spectrum of
diseaseandauniformapproachtotreatmentisnotappropri-
ate. Some patients require no treatment other than excision
alone, others beneﬁt from complete excision plus radiation
therapy, and some will require mastectomy [25].
The challenge is using available clinical and pathologic
datatodeﬁnetherapyforspeciﬁcsubsetsofriskandquantify
the evolving knowledge of prognostic factors.
Management strategies need to consider the breast and
axilla, the need for adjuvant RT, and the utility of systemic
adjuvant therapy. The gold standard in surgical treatment
includes oncological radicality, optimizing cosmetic results
with a positive psychological outcome. Today, through the
joint activities of a multidisciplinary team and scientiﬁc
expertiseauniformoperatingpatternissearched,butdespite
these general principles, the optimal management of DCIS
remains controversial [5, 26].
3.2. Radical Treatment. Despite the signiﬁcant transition
from symptomatic patients toward those with screen de-
tected pathology, paradoxically in some cases DCIS is
managed with the radical intent applied to invasive breast
cancer (IBC) [27]. Douek and Baum determined the impact
of England screening on the type of surgery undertaken and
reported an increase of 373% in the number of operations
performed for DCIS and of 422% for the mastectomy
practice over a period of 11 years [28].
In the French survey experience mastectomy (MX),
conservative surgery alone (CS) and CS with radiotherapy
(CS + RT) were performed in 30.5%, 7.8%, and 61.7% of
1289 patients, respectively (Table 3)[ 29].
Although the data indicate a sharp decline in the proce-
dure rate, given the dramatic increase in the number of diag-
noses, the actual incidence of MX at 7.8 per 100000 women
did not change, and several studies conﬁrmed an approxi-
mately application in one-third of cases. General guidelines
recommend that patients with extensive or multifocal DCIS
involving 4-5cm of disease or more than one quadrant
should be oﬀered mastectomy. Moreover, women with
potential contraindications to breast irradiation or a strong
preference for mastectomy over breast conservation have
been considered appropriate candidates for this procedure.
The risk of a radical intervention is deﬁned higher in
some clinical scenarios like diﬀuse and suspicious-appearing
microcalciﬁcations, suboptimal tumor to breast size ratio
with an unacceptable cosmetic results, the inability to obtain
margin control by lumpectomy or reexcision(s) [30].
In the French survey the authors did not assess multifo-
cality and multicentricity but analyzed the notion of residual
tumor on the specimen in case of multiple surgery, maximal
tumorsize,andﬁnalmarginstatustopredictthebestsurgical
option (especially mastectomy). This study reported MX
rates of 10% for lesions <10mm compared to 72% for
>20mm, 11% for low-grade compared to 54% for high-
grade lesions, and 43% for comedo carcinoma against 28%
of other pathological subtypes [29].
The comparison of data in patients treated with MX
and BCS showed a signiﬁcant improvement in local control
obtained with mastectomy (relapse free rate of 98.2% versus
89.7% at 10 years P = 0.02) without obvious impact on
survival (98.7% in both groups) [31].
Thanks to the advances in diagnosis and improvements
in reconstructive surgery, mastectomy will continue to be an
important and acceptable treatment option in some cases.
Cutulli et al. results conﬁrm a 98% local control rate as
reported by other series. After a 91-month median follow-
up, local recurrence (LR) rates were 2.1, 30.1, and 13.8%
in the MX, CS, and CS + RT groups of 716 women. The
importance of case selection is discussed in relation to the
high invasive recurrence rate following conservative surgery
with (LR 59%) or without radiotherapy (LR 60%) and
relative reported incidence of metastases reported in this
subgroup (19%) [32]( Table 4).
Furthermore, among all surgically treated patients the
cumulative risk of contralateral disease increased with an
annual rate of 0.6% and some women undergo prophylactic
mastectomy (CPM) to prevent cancer in the opposite breast.
ArecentsurgereportedaprogressionofCPMratefrom2.1%
to 5.2% between 1998 and 2005, and factors contributing to
this change most certainly include improved reconstructive
outcomes and more widespread use of magnetic resonance
[33].
Various approaches for radical surgery are currently used
and include simple mastectomy (excision of breast tissue andInternational Journal of Surgical Oncology 5
Table 3: Treatment modalities according 1289 DCIS patients.
Breast surgery CS 7.8% CS/RT 61.7% MX 30.5%
(France) Range (84–96%) Range (20–37%)
(United States) Range (39–74%) Range (26–45%)
Axillary surgery SLNB 21.3% AD 10.4%
Hormonal therapy HT 13.4%
(France) range (6–34%)
Reference [29].
Table 4: 8 years results of conservative and radical treatments in 716 DCIS.
MX (145) CS (136) CS + RT (435)
Type of surgery 20.25% 18.09% 60.75%
8-year local recurrence rate 2.1% (3) 30.1% (41) 13.8% (60)
Noninvasive local recurrence 0% (0) 41.46% (17) 40% (24)
Invasive local recurrence 100% (3) 58.53% (24) 60.0% (36)
Nodal recurrence 0 3.7% 1.8%
Metastases 1.4% (2) 4.4% (6) 1.4% (6)
(All distant metastases occurred after previous invasive LR)
Metastases among cases of invasive LR in CS and CS + RT 19% (12/60)
Reference [32].
overlying skin), skin-sparing approach (SMM), and, most
recently, nipple-preserving techniques. In addition MX for
DCIS is particularly suited to immediate breast reconstruc-
tion with an implant or autologous ﬂap, as adjuvant RT
and axillary involvement are less likely. The preservation of
the natural skin envelope and inframammary fold during
skin-sparing mastectomy would seem an ideal option to
improve the aesthetic outcome of the instant reconstructive
time, provided that clear margins are achieved. There has
been a concern that it compromises the completeness of a
mastectomy resulting in an increase in local breast cancer
recurrencebutlargestudiesconcludedthatSSMorDCISwas
an oncologically safe procedure with an LR rate similar to
conventional MX (1–3%) [34].
The original Van Nuys prognostic index was created by
combining lesion parameters and local recurrence as the
markers of treatment failure. In the attempt to quantify the
knownimportantprognosticfactorsinDCIS,theUSC/VNPI
is oﬀered as a guideline in a scientiﬁcally based discussion
with the patient in order to deﬁne appropriate treatment.
In Silverstein, patients with USC/VNPI scores of 10, 11, or
12 showed the greatest absolute beneﬁt from postexcisional
radiationtherapy,buttheirLRratecontinuestobeextremely
high and a recommendation for mastectomy should be
considered [25]. In the future other factors like molecular
markers may be integrated into the index to the extent that
they are shown to be statistically important predictors of
local relapse.
3.3. Breast Conserving Surgery. In spite of its often larger
size, DCIS is a local disease lacking of two important
components of the fully expressed malignant phenotype like
stromal invasion and distant metastases. Its distribution is
almost always segmental (unicentric) and complete excision
is theoretically possible to achieve local clearance [24].
Faverly et al. have attributed the reliability of histological
margin assessment to proliferation type, showing that con-
tinuous and multifocal growth pattern are usual in poorly
and well diﬀerentiated in situ, respectively. However, in this
series, only 8% of DCIS in 60 mastectomy specimens have
a multifocal distribution with gaps greater than 10mm, and
this theoretically low likelihood of false free margin should
encourage the use of conserving treatment for eradicable
tumors [35].
Available data suggest that local control is optimized by
the lumpectomy adequacy, regardless of the number of re-
excisionsrequiredtoachievemargin-negativestatus[36,37].
Several investigators have also demonstrated that a diagnos-
tic needle biopsy is associated with a higher success rate for
subsequent BCS, improving single lumpectomy procedure
results. The surgeon will plan a therapeutic partial breast
resection with a more aggressive approach when the aim is
to achieve margin control compared with when the goal is
to sample adequately for a tissue diagnosis [38]. However,
controversy remains regarding the oncological adequacy of
BCS alone and the variable local relapse risk in randomized
clinical trials evaluating DCIS treatment. In the National
Surgical Adjuvant Breast Project (NASBP B-17) the overall
recurrence rate for patients treated with excision only was
32% at 12 years, and 16% for patients treated with excision
plus irradiation. At 4 years of follow-up, 9% of patients
treated with excision plus radiation therapy had a local
recurrencecomparedwith16%ofDCIStreatedwithexcision
only in the EORT results, showing a statistically signiﬁcant
(approximately 50%) reduction in LR for patients who
received RT [30].6 International Journal of Surgical Oncology
Optimal local control is essential because in most report-
ed series, approximately half of all local recurrences are
invasive ineachtreatmentgroup. Infact,breastpreservation,
with or without RT, yields a better cosmetic results but is
accompaniedbyanincreaseintheprobabilityoflocalfailure.
The clinical value of recurrent DCIS is diﬀerent from
primary lesions and the prognostic implications of invasive
disease are signiﬁcant.
In particular the overall risk of metastasis has been
reported to 0–3.6% for in situ LR, compared to 13.2–18%
after invasive LR, and the axillary lymph node involvement
with invasive LR is estimated from 11 to 30% [39, 40]. In Sil-
verstein series the 8-year breast cancer-speciﬁc mortality and
distant disease probability for 74 patients with LR previously
treatedforDCISwere8.8%and20.8%,respectively,whilefor
the 35 invasive recurrences subgroup they were 14.4% and
27.1% [41].
Multivariate analysis showed that margin width, age,
nuclear grade, and tumor size were all independent predic-
tors of local recurrence (P<. 001), with margin width as the
single most important variable [42].
In 445 patients dataset with pure DCIS treated with exci-
sionalone,Heatheratal.describedtheincrementalbeneﬁtof
larger margins. The median tumor size was 10mm and after
amedianfollow-upperiodof57monthsonly9of197(4.6%)
patients with a greater than 10mm margin experienced local
failure (Table 5). The probability of remaining free of local
recurrences at 5 years was 93% without postoperative radio-
therapy. The relative risk of developing an LR stratiﬁed by
surgical margins was plotted as a continuous variable with
a clear trend on decreasing the hazard ratio for local failure
[43].
According to this approach, the most likely cause of
local recurrence after excision alone for DCIS is inadequate
surgery resulting in residual disease. In a previously reported
data from 181 intraductal breast carcinoma, 76% of patients
with initially involved margins had residual DCIS at mastec-
tomy or reexcision, as did 43% of patients with initially clear
margin (>1mm) [44].
Neuschatz et al. analyzed reexcision specimens of 253
patients treated with lumpectomy for DCIS identifying
residual disease in 63% of patients with transected margins,
compared to 41% with greater than 0 to 1mm, and to 31%
with greater than 1 to 2mm margins (Table 6)[ 17].
Yet one of the most important questions in the complex
decision-making progress regards which patients selected for
breast preservation require postexcisional radiation therapy.
In our opinion, exploring the prognostic implications of
histopathological features in BCS should be an excellent pre-
dictor of outcome, and with further corroboration, margin,
width alone could possibly be used to determine the need for
adjuvant RT in diﬀerent risk subgroups.
T h es u r v i v a lc u r v e sf r o mt h eV a nN u y ss e r i e ss h o w e d
that, regardless of the presence of high nuclear grade, come-
donecrosis, large tumor size, or young age, the risk of
local relapse remains slight if wide margins of resection
are achieved. Consistent with the NSABP B-17 and EORTC
trial ﬁndings, the absolute reduction of LR by RT increased
with time from 7% at 4 years to 11% at 10.5 years but
successive studies recognized that postoperative RT may not
signiﬁcantly improve the local outcome in all types of DCIS
[27].
DiSaverioetal.conﬁrmedthevariablebeneﬁtsofadding
RT for diﬀerent subsets of patients and so questioning the
suitability of a uniform treatment policy. There was no
advantage in the low VNPI score subgroup while it should
be noted that in the groups with the higher VNPI score the
beneﬁt from adjuvant RT in avoiding local recurrence could
begreater.Disease-FreeSurvival(DFS)at10yearswas94.7%
in CS compared to 92.3% in CS + RT in low VNPI (4-5-6)
score group, 78.5% and 86.8% in the intermediate VNPI (5-
6-7), and 50% against 100%, respectively, in the high VNPI
(10-11-12) [31].
In the evaluation of USC/VNPI, Melvin et al. focused
on the impact of margin status score on local recurrence.
With margins 1–9mm(score2),therewasasigniﬁcant trend
toward a beneﬁt from irradiation. With margins less than
1mm (score 3), there was a highly signiﬁcant decrease in the
probability of LR if radiation therapy was added [24].
These data suggest that margin width should be valued
as an excellent predictor of local recurrence probability, and
consequently, of the likelihood of residual DCIS. Silverstein
et al. reported an 8% local recurrence rate for all conserva-
tively treated DCIS lesions with margins of 10mm or greater
(VNPI score 1) [45] and Lagios and Silverstein showed
a 5% local recurrence rate for all conservatively treated
patients with the same margin status and lumpectomy alone
compared to 4.5% in those treated by lumpectomy and
irradiation [46].
In the selection process of pure DCIS cases, Van Nuys
Prognosticsystemcanbeappliedinconjunctionwithclinical
experience to study tumor morphology and detection rate
of local recurrence as the primary end points. Radiation
therapy is not without side eﬀects changing the texture of the
breast and making subsequent mammography more diﬃcult
to interpret. Furthermore, its use may preclude the chance to
implement a conservative treatment should it be needed in
the future [47].
Consequently, subsets of patients who are not likely to
receive any signiﬁcant beneﬁt from radiation therapy can be
identiﬁed.
DCIS cases with VNPI scores of 3 or 4, low-grade
lesions, small noncomedo lesions with uninvolved margins
or well-diﬀerentiated lesions can be considered for treatment
with excision only. This can be an important therapeutic
cornerstone since such patients may account for more than
30% of the total number [48].
Patients with intermediate scores (5, 6, or 7) received
a statistically signiﬁcant 17% LR-free survival beneﬁt when
treated with radiation therapy (P = 0.017) but treatment
recommendations for the intermediate group are the most
diﬃcult. DCIS cases with scores of 8 or 9, although showing
the greatest relative beneﬁt from RT, experienced LR rate
in excess of 60% at 8 years and should be considered for
mastectomy, generally with immediate reconstruction or
reexcision if technically possible [41].
This controversy over the treatment selection may lead
to a new conceptual approach on the operational chance ofInternational Journal of Surgical Oncology 7
Table 5: Breast conservative surgery (BCS) results without RT.
Authors Patients Margin width Local recurrence Follow-up
Fischer et al. (2001) [58] 818 1mm 31% 10 years
BiJker et al. (2001) [59] 1010 3mm 13% 10 years
Houghtons et al. (2003) [60] 1701 1mm 22% 4 years
Warren et al. (2005) [61] 1103 15% 7 years
Sabin et al. (2011) [62] 670 3mm High grade 18%
Low grade 10.5% 7 years
Heather et al. (2005) [43]
(median tumor size 10mm) 197 >10mm 4.6% 5 years
Table 6: Reexcision specimens analysis in patients treated with lumpectomy for DCIS.
Margin Width (mm) Residual Disease
(i) Silverstein et al. [44] ≥1mm 43%
<1mm 76%
(ii) Neuschatz et al. [17] 0mm (transected) 63%
0-1mm 41%
1-2mm 31%
surgically modifying VNPI score and thus inﬂuencing the
choice of more or less invasive strategy.
Potentially, in some cases, a patient can choose a reex-
cision, in order to downscore her lesion where the safety
predictive criteria cannot be guaranteed. Successful down-
scoring of a patient with a USC/VNPI or 10 or 11 could
result in substantial reduction in the risk of local recurrence,
perhaps changing a recommendation from mastectomy to
radiation therapy. Similarly, patients with close or involved
margins with USC/VNPI scores of 7 or 8 after initial excision
could opt for reexcision and a successful downscoring by
achieving widely clear margins. This could result in a ﬁnal
score suﬃciently low to avoid breast irradiation.
Moreover a dynamic surgical technique may be the basis
for consolidating the diagnostic paradigms and further de-
crease the downtreatment risk.
In some case, reexcision will upscore the tumor, increas-
ing the USC/VNPI by revealing a larger tumor size, a higher
nucleargrade,thepresenceofpreviouslyundetectedcomedo
necrosis, or an involved margin, suggesting in this way that
mastectomy is preferable to select [25].
We deem prudent that the choice is acquired together,
havingsurgeontoassistthepatienttoachievehismoreorless
conservative goal, according to the subjective and variable
security needs and by counseling in a rational manner.
Moreover, due to the molecular heterogeneity of DCIS
as well as the increasing trend toward individualized cancer
treatment [49, 50], a Nomogram for predicting the risk of
local recurrence after breast-conserving surgery published
by Rudloﬀ et al. integrates ten clinicopathologic variables to
providetheprobabilityofLRat5and10yearsafterBCS.The
riskestimateisspeciﬁcontheindividualpatientandtheﬁnal
regression model was chosen according to the clinical and
statistical signiﬁcance of categorical variables like age at the
time of surgery, family history, initial presentation, radiation
therapy, adjuvant endocrine therapy, nuclear grade, necrosis,
margins, number of excisions, time period of surgery, and
their interdependent relationships. This tool may assist in
individual decision making regarding various surgical or
treatment options and help avoid over- and undertreatment
of noninvasive breast cancer showing it to have favorable
predictive accuracy and good model calibration [51].
Furthermore, we think that a more invasive procedure
can be oriented on the axillary side as selective sentinel
lymph node biopsy (SLNB) whose diagnostic mode has less
aesthetic responsibility but a great role on therapy selection
process.
In retrospective analysis of diagnostic procedures the
invasion underestimation in needle biopsies of DCIS and the
improvement in the sentinel practice have led some authors
to support the lymphatic mapping at the surgery time [52].
In Lee et al. study there was no association between age,
nuclear grade, tumor size, or presence of a mass in determin-
ing the likelihood of invasion, and of 59 patients diagnosed
with DCIS by stereotactic biopsy, 29% were subsequently
found to have invasive disease after surgery [53].
The status of the axillary lymph nodes remains the
most powerful prognostic indicator of invasive breast
cancer, but the role of axillary staging with SLNB for DCIS
is controversial [54]. Nonetheless, surgeons have been
removing lymph nodes in patients with a primary diagnosis
of DCIS for a variety of reasons and with variable results
[55]. This is consistent with ﬁndings from the recent French
survey which reported overall rates of 21.3% for SLNB and
10.4% for axillary dissection (AD) [29]. Positive sentinel
n o d e sh a v eb e e nr e p o rt e di n0 %t o1 3 %o fDC I Sp a t i e n t sb u t
among published studies, the incidence of SLNB metastasis
among patients with initial diagnosis is substantially higher
than among those with a ﬁnal diagnosis like after excision
or mastectomy (9.8% versus 5.0%) [3]. The information8 International Journal of Surgical Oncology
from axillary dissection or SLNB was of little value in the
treatment of patients in whom no invasive cancer was found
but it remains an attractive option when considering DCIS.
The absolute indication for SLNB remains histological
conﬁrmation of concurrent or recurrent invasive disease.
Therefore, in patients diagnosed with DCIS on core biopsy
examinations SLNB should be reserved for those at high risk
of invasive disease, including patients with palpable lesions,
DCIS larger than 40mm, high nuclear grade, comedo
morphology,necrosisorrecurrentdisease,orpatientsunder-
going mastectomy where SLNB could not be postponed
[55].
Moreover axillary node involvement is higher with
DCISM (5.1%) than that with DCIS (1.4%) and inadequate
sampling could result in misdiagnosis and consequent un-
der-treatment of patients [5]. The incidence rate of microin-
vasion among all DCIS cases is approximately 14% [56],
and this theoretical foundation can support the signiﬁcance
of stratiﬁcation risk in the practice of nodal spread staging
procedure, in order to change the prognosis.
4. Conclusion
Since our knowledge of ductal carcinoma in situ (DCIS)
continues to evolve, treatment decisionmaking has become
increasingly complex and controversial for both patients and
physicians. It represents a broad biologic spectrum of disease
with a wide range of molecular heterogeneity, treatment
approaches, and clinical recommendations but the need of
local control should guide our decisions regarding therapy
and help to risk stratify patients.
It is often diﬃcult to justify mastectomy during an era of
increasing practice of conservation for the more aggressive
lesion (invasive breast cancer), but not all patients are candi-
dates. The other side is to understand and deﬁne more accu-
rately the application range of conservative treatment and its
dynamic potential. Target is to treat patients eﬀectively and
decrease the risk of local recurrence, selecting the approach
that will signiﬁcantly beneﬁt each patients group and not
subject them to unnecessary risk. Speciﬁcally, the sophisti-
catedquestions thatpatients anddoctors asktoday arewhich
subgroups of DCIS will beneﬁt from postexcisional radiation
therapy and how much and which can be treated by excision
alone.Certainlythegoldstandardinclinicalpracticemustbe
designedwithanintegratedapproachtodiagnostic andther-
apeutic features and functional skills aggregation. Nomo-
gramsaregraphicaldepictionsofpredictivemodelsthatpro-
vide overall probability of a speciﬁc outcome for an individ-
ual patient, and in consultation with a physician, these tools
can be used by patients to make decisions regarding various
treatment options. The objective is to overcome the conﬂict
between extent of resection, need of adjuvant strategies, and
ﬁnal aesthetic result with good oncological radicality.
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